This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The second quarter of 2025 saw some huge successes and fails in the psychiatric treatment pipeline. What percentage of 2025 Q2 psychiatric pipeline news was positive vs negative? The meeting will take place on July 25, 2025. Learn more in this exclusive article.
Related Videos Related Content Advertisement June 13th 2025 Tardive Dyskinesia: Treat Functional Impairment, Not the AIMS Score John J. Newsletter Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients. Subscribe Now! Goldberg, MD, and Anita H.
Related Videos Related Content Advertisement June 6th 2025 Brief Book Reviews: June 2025 Edmund S. Gold, MD, MS May 5th 2025 Brief Book Reviews: May 2025 Edmund S. Higgins, MD April 8th 2025 Lorazepam and the White Lotus in our Tariff Times H. Higgins, MD March 3rd 2025 Brief Book Reviews: March 2025 Edmund S.
Emerging research on RNA biomarkers, AI applications, and genetic mutations shows promise for developing new diagnostic tools for bipolardisorder. Non-pharmacological approaches and combination therapies are emphasized in treatment, with recent FDA approvals for new medications targeting bipolar symptoms.
Presented at: Southern California Psychiatry Conference; July 11-12, 2025; Huntington Beach, CA. Accessed July 11, 2025. January 21, 2025. Related Videos Related Content Advertisement July 11th 2025 Are You Ready for the Southern California Psychiatry Conference? Psychiatric Times. May 19, 2022. Psychiatric Times.
Maguire, MD , Heidi Anne Duerr, MPH Maguire discussed the differential diagnosis of bipolar depression at the Southern California Psychiatry Conference. Similarly, because patients with bipolardisorder often self-medicate, looking for a family history of substance abuse can be helpful. “iI's Accessed July 12, 2025.
June 23, 2025. September 11, 2025. With MDMA on hold, what’s next for psychedelics? Psychiatric Times. link] Newsletter Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients. Subscribe Now!
July 8, 2025. sNDA submitted: lumateperone as adjunctive therapy for major depressive disorder. Related Videos Related Content Advertisement July 7th 2025 The Psychiatric Pipeline in Review: Quarter 2, 2025 Leah Kuntz September 27th 2021 Treating ‘Morally Objectionable’ Patients James L. News release. Psychiatric Times.
June 30, 2025. Accessed July 1, 2025. children and adolescents in 2022: diagnosis, severity, co-occurring disorders, and treatment. FDA requires expanded labeling about weight loss risk in patients younger than 6 years taking extended-release stimulants for ADHD. FDA Drug Safety Communication. CDC Growth Charts. September 2024.
She has been on an antipsychotic medication to treat her bipolardisorder for 10 years, resulting in stability of mood symptoms that were previously poorly controlled. Teva Pharmaceuticals; 2025. Neurocrine Biosciences Inc; 2025. How can this be? Let’s review a few case examples. J Clin Psychiatry. 2017;78(8):1136-1147.
Accessed June 11, 2025. Author(s): Joseph F. Goldberg, MD , Stephen M. Stahl, MD, PhD, DSc (Hon) Now more than ever, capturing and scaling the ingredients that make for compelling and impactful teaching for trainees is vital to our future. Division of Clinical Pharmacology, Indiana University School of Medicine Updated 2021.
Related Videos Related Content Advertisement July 3rd 2025 Young Researchers Featured at Conference of Society for Digital Mental Health Kenneth J. Steven Moffic, MD Related Content Advertisement July 3rd 2025 Young Researchers Featured at Conference of Society for Digital Mental Health Kenneth J.
Related Videos Related Content Advertisement July 17th 2025 First Patient Dosed in Phase 2b Study of GlyphAllo for Patients With Major Depressive Disorder, With or Without Anxious Stress Leah Kuntz April 6th 2021 David Hellerstein, MD: Psychedelic Treatments for Psychiatric Disorders Angela A.
Sanom/Adobestock BREAKING NEWS The US Food and Drug Administration granted Transcend Therapeutics with the Breakthrough Therapy designation for their compound TSND-201 for (methylone) for the treatment of posttraumatic stress disorder (PTSD) following positive results from its IMPACT-1 study. Jul 10, 2025. Accessed July 10, 2025.
FDA Officially Eliminates Clozapine REMS On June 13, 2025, the US Food and Drug Administration (FDA) officially eliminated the clozapine REMS, and all REMS operations ceased. The company anticipates an FDA decision on NRX-100 by the end of 2025. We compiled a recap of the latest news here, just in case you missed any of the updates.
Related Videos Related Content Advertisement June 17th 2025 ADHD With BipolarDisorder: Genetics, Diagnosis, and New Thinking on Treatment David N. Subscribe Now!
NRx is targeting suicidal depression and PTSD with NRX-100, anticipating an FDA decision by the end of 2025. The company continues to anticipate an FDA decision on NRX-100 by the end of 2025. The timelines announced for the CNPV program are consistent with NRx's previous guidance of FDA decisions (PDUFA date) by year-end 2025.
Related Videos Related Content Advertisement June 17th 2025 ADHD With BipolarDisorder: Genetics, Diagnosis, and New Thinking on Treatment David N. Subscribe Now!
Related Videos Related Content Advertisement June 17th 2025 ADHD With BipolarDisorder: Genetics, Diagnosis, and New Thinking on Treatment David N. Subscribe Now!
Presented at: Southern California Psychiatry Conference ; July 11-12, 2025; Huntington Beach, CA. Accessed July 11, 2025. Accessed July 11, 2025. Related Videos Related Content Advertisement July 11th 2025 Are You Ready for the Southern California Psychiatry Conference? Psychiatric Times. December 4, 2023. August 4, 2023.
A Harmful Dysfunction Analysis Author(s): Jean-Arthur Micoulaud-Franchi, MD, PhD , Christophe Gauld, MD, PhD +2 More Key Takeaways Sleep medicine lacks a structured definition for disorders, complicating diagnosis and classification compared to psychiatry's DSM framework. Subscribe Now! Siddiqui, BSc Shizuka Tomatsu, MD Matthew J.
It has been 20 years since the last new agent was approved for treating PTSD, so all eyes on the meeting, which is scheduled for Friday, July 18, 2025. July 18, 2025: Meeting of the Psychopharmacologic Drugs Advisory Committee Meeting Announcement. Accessed July 16, 2025. July 16, 2025. Accessed July 16, 2025.
Related Videos Related Content Advertisement July 3rd 2025 Ode to Self-Compassion Frank A. Berlin, MD June 14th 2025 An Ageless Dream Frank A. Berlin, MD May 14th 2025 "Transference" Richard M. Berlin, MD April 18th 2025 In or Out Frank A. Berlin, MD June 14th 2025 An Ageless Dream Frank A.
Accessed July 1, 2025. Related Videos Related Content Advertisement June 13th 2025 Tardive Dyskinesia: Treat Functional Impairment, Not the AIMS Score John J. Dr Robinson is assistant professor and director of the Psychiatric-Mental Health Nurse Practitioner specialty at the University of Maryland School of Nursing. References 1.
A 1989 publication by psychiatry icons Gelenberg et al 8 convincingly demonstrated that for maintenance treatment of patients with bipolardisorder with a serum lithium concentration of 0.4 Comparison of standard and low serum levels of lithium for maintenance treatment of bipolardisorder. Accessed June 6, 2025.
Accessed June 3, 2025. Accessed June 3, 2025. Accessed June 3, 2025. Accessed June 18, 2025. July 1, 2024. Nakagawa K, Yellowlees P. Inter-generational effects of technology: why millennial physicians may be less at risk for burnout than baby boomers. Curr Psychiatry Rep. 2020;22(9):45. Defining “technology.”
Related Videos Related Content Advertisement June 5th 2025 Enhancement Psychiatry H. Steven Moffic, MD June 3rd 2025 Whither Psychiatry? Steven Moffic, MD June 2nd 2025 The Psychiatrist Ethics of “Take Care of Yourself and Each Other” H. Steven Moffic, MD May 30th 2025 DEI Concerns in Psychiatric Organizations H.
Related Videos Related Content Advertisement June 16th 2025 If You Were a Cookie, What Kind Would You Be? Berlin, MD May 15th 2025 You could have killed me today Jaslyn Kindel, MD December 13th 2012 Last Concert of the Summer (Podcast) Richard M. Berlin, MD April 18th 2025 In or Out Frank A. Clark, MD April 17th 2025 Bad Debts.
Related Videos Related Content Advertisement June 10th 2025 Rallying for Public and Immigrant Mental Health Amidst the Parading of Military Might H. Steven Moffic, MD June 6th 2025 Redemption in Psychiatry H. Steven Moffic, MD June 5th 2025 Enhancement Psychiatry H. Steven Moffic, MD June 3rd 2025 Whither Psychiatry?
The symptom(s) cannot be better accounted for by another mental disorder, including depressive or bipolardisorder with psychotic features, and cannot be attributed to the physiological effects of substances or other medical conditions. Child Adolesc Psychiatr Clin N Am. 2024;33(4):645-658.
Related Videos Related Content Advertisement July 12th 2025 Exploring NMDA Antagonists for MDD Heidi Anne Duerr, MPH October 7th 2021 Blue Light Blockers: A Behavior Therapy for Mania Chris Aiken, MD Kellie Newsome, PMH-NP July 7th 2025 Transformation 2.0: The GLP-1 RAs as Psychiatric Medications?
Dzmitry/AdobeStock On Friday July 18, 2025, the US Food and Drug Administration (FDA) advisory committee will discuss the supplemental New Drug Application (sNDA) for brexpiprazole (Rexulti) tablets, submitted by Otsuka Pharmaceutical Company, for the treatment of adults with posttraumatic stress disorder (PTSD), in combination with sertraline.
Related Videos Related Content Advertisement July 15th 2025 Overcoming Disaster Fatigue, Part 2: Some Solutions H. Steven Moffic, MD July 14th 2025 Overcoming Disaster Fatigue, Part 1: The Challenges H. Steven Moffic, MD July 11th 2025 O Superman! Steven Moffic, MD July 11th 2025 O Superman!
McIntyre, MD, FRCPC Key Takeaways Incretin-based treatments, especially GLP-1 RAs, may address comorbidities in mental disorders and have direct CNS effects, potentially modifying disease progression. J Affect Disord. BipolarDisord. The GLP-1 RAs as Psychiatric Medications? The GLP-1 RAs as Psychiatric Medications?
Steven Moffic, MD Series | Psychiatric Views on the Daily News Key Takeaways Rising disorder prevalence and reduced resources challenge psychiatry amidst social crises, leading to emotional overwhelm. Related Videos Related Content Advertisement July 14th 2025 Overcoming Disaster Fatigue, Part 1: The Challenges H.
Accessed June 13, 2025. Related Videos Related Content Advertisement June 12th 2025 Redemption in Psychiatry, Part 2: Collegial Reactions H. Steven Moffic, MD June 10th 2025 Rallying for Public and Immigrant Mental Health Amidst the Parading of Military Might H. Steven Moffic, MD June 6th 2025 Redemption in Psychiatry H.
Ben Gingell/AdobeStock On July 17, 2025, the 988 National Suicide & Crisis Lifeline will stop providing tailored support options to LGBTQ+ youth and young adults. June 17, 2025. Accessed June 19, 2025. June 19, 2025. Accessed June 19, 2025. June 18, 2025. Accessed June 19, 2025.
Could some of the characters meet criteria for bipolardisorder? Posttraumatic stress disorder? Gold, MD, MS April 8th 2025 Lorazepam and the White Lotus in our Tariff Times H. Steven Moffic, MD April 7th 2025 Brief Book Reviews: April 2025 Edmund S. Depression? Quite possibly.
Mcintyre, MD, FRCPC Key Takeaways GLP-1 and GIP are key incretins involved in glucoregulation, with GLP-1 RAs showing significant therapeutic potential in T2DM and beyond. Subscribe Now!
Gratefully, it not only goes on in my Milwaukee, but should be increased in recognition because it is also included for the first time in the large and beloved SummerFest music events, as discussed in the June 3, 2025, article in the Milwaukee Journal Sentinel “Americans need transformative talks on race. June 3, 2025.
Related Videos Related Content Advertisement July 10th 2025 TSND-201 Receives Breakthrough Therapy Designation From FDA for PTSD Heidi Anne Duerr, MPH September 28th 2021 A Forensic Psychiatrist Takes the Stand James L. Coombs, MD Jennifer Sotsky, MD, MS May 13th 2025 Diagnosis in BipolarDisorder: Dealing With Comorbidity David N.
Daniel Morehead, MD June 6th 2025 Brief Book Reviews: June 2025 Edmund S. Daniel Morehead, MD June 6th 2025 Brief Book Reviews: June 2025 Edmund S. Steven Moffic, MD Prevention of wars would reduce the extraordinary loss of lives and major trauma. This video series is taking a short break while Dr Moffic travels.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content